Skip to main content
Boston Scientific to drop bioplastic-stent development program

Boston Scientific will abandon its long-running program to develop Renuvia, a biodegradable plastic stent, despite promising study results as it intends to focus on treating larger and "more socially impactful problems," such as heart failure and stroke, said Dr. Ian Meredith, global chief medical officer at the company. The company, which will release Renuvia study results this fall, made the decision after Abbott Laboratories found its bioresorbable Absorb GT1 BVS demonstrated statistically significant safety issues at two years.

Full Story: